María-victoria Mateos MD, PhD

Dr. María-Victoria Mateos, MD, PhD, is Head of Myeloma and Clinical Trials Unit at the Haematology Department and Professor of Medicine at the University of Salamanca, Spain. She serves as co-coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials, especially in the setting of transplant-ineligible and smoldering myeloma, and these trials have profoundly influenced current options for the management of these patient populations.

She has published over 400 papers in international journals with an H index of 105. She is also a member of the IMWG (International MM Working Group), IMS (International MM Society), EHA, and ASH. She served on the ASH Scientific Committee on plasma cell diseases between 2015 and 2019 and on the EHA’s Scientific Program Committee and Advisory Board since 2013 until 2020, being chair of the Scientific Program Committee in 2019.

She has been a Councilor on the EHA Board since 2015 for a four-year mandate, a member of the European School of Haematology (ESH) Scientific committee, and a member of the ASCO scientific program committee. She received the Briand Durie Award in 2019, the Bart Barlogie Award in 2022, recognizing excellence in myeloma research, and the Kyle Lifetime Achievement Award in 2023. She has been the President of the National Society of Hematology since October 2022 for a four-year mandate.

She has been a member of the IMS board from 2016 to 2019, and subsequently elected as secretary and currently treasurer as part of the IMS executive board during 2023-2026.